Q-omics provides the consensus-scored CPEB2-DT profile across patient tissues and cancer cell-line models. CPEB2-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CPEB2-DT is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, CPEB2-DT RNA expression shows 16,750 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where CPEB2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPEB2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPEB2-DT survival associations across molecular data types. CPEB2-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPEB2-DT RNA expression–survival associations across cancer types. High CPEB2-DT expression shows unfavorable associations in UVM, BLCA and LGG, but favorable associations in PAAD, HNSC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for CPEB2-DT RNA expression.
This table summarizes CPEB2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CPEB2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPEB2-DT shows lower tumor expression in ESCA and COAD and higher tumor expression in LIHC, BRCA, LUSC and KIRC. The LIHC box plot shows higher CPEB2-DT RNA expression in tumor versus normal tissue (log2 FC = +0.076, t-test p < 0.001).
This table shows molecular features associated with CPEB2-DT in patient tissues and cancer cell lines. In patient samples, CPEB2-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
